LABU a 3X leveraged ETF of biotechnology stocks LONG

AwesomeAvani Updated   
BATS:LABU   Direxion Daily S&P Biotech Bull 3X Shares
LABU on a 240-minute chart has been in a trend up gaining 100% in 3 months. Both the fast and

slow ( green and red) are above the 50 level. Biotechnology is expected to be a hot subsector

this year as healthcare recovered further from the COVID pandemic anything from startups to

big pharma- from vaccines to new drugs for diabetes, liver disease and obesity. Leveraged

funds have time decay from the leveraging and management fees and are meant to be for

short-term trading. Nonetheless, 100% in 3 months is an excellent return. I add to my position

when I see a pullback on the 15-30 minute chart. If price rises more than 2% in a day I may

take 1-2 shares off the position to realize some profit and recycle ( compound) into the next

buy. According to those that follow sectors, LABU should outperform this year.

Trade active:
Not unexpectedly LABU had a surge, 10% of the position closed to buy a single call option contract for LLY and another for NVAX, and another for MRNA. The latter heavily beat on the earnings report. Will deploy fresh capital into LABU upon
a dip down into the support of the liquidity-adjusted moving average cloud. Rinse
and repeat.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.